Lexaria Bioscience (NASDAQ: LEXX) Expanding Portfolio with Four New Patents

April 20, 2023 12:41:52

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that it has received notifications of four new patents either awarded or allowed. In Japan, the company secured a new patent under its Patent Family #3: Stable Ready-to-Drink Beverage Compositions Comprising Lipophilic Active Agents. This is Lexaria’s fifth awarded patent in Japan, providing strength to its growing Japanese patent portfolio. In Australia, Lexaria has received a new patent under its Patent Family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This is Lexaria’s 10th patent in Australia and its second in this patent family. In Canada, Lexaria has been advised of allowance of a new patent under its Patent Family #8: Compositions Infused With Nicotine Compounds and Methods of Use Thereof. This is Lexaria’s second patent in this family and follows a similar issuance in Australia in 2022. In the USA, Lexaria has been advised that a new patent under its Patent Family #21: Compositions and Methods for Treating Hypertension has been allowed. To be the first patent in this family, Lexaria believes this could be of particular importance related to its pursuit of utilizing DehydraTECH-CBD in relation to its expected upcoming FDA Investigational New Drug application.

To view the full press release, visit https://ibn.fm/93T6V

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About TinyGems

TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.

To receive SMS text alerts from TinyGems, text “Gems” to 844-397-5787 (U.S. Mobile Phones Only)

For more information, please visit https://www.TinyGems.com

Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer

TinyGems
Los Angeles, California
www.TinyGems.com
310.299.1717 Office
[email protected]

TinyGems is part of the InvestorBrandNetwork.